GlycoNex, Inc.

Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical data on GNX1021 will be presented on April 28 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. GNX1021 is an antibody-drug conjugate (ADC) targeting branched Lewis B/Y (bLeB/Y), a unique tumor-associated glycan antigen overexpressed in gastric cancer and other solid tumors. The poster will highlight in vivo efficacy and safety findings from gastric cancer models that demonstrate GNX1021's tumor control activity. "We are very pleased that research involving GNX1021, our glycan-targeting ADC, was accepted for presentation at AACR 2025," said Dr. Mei-Chun Yang, CEO of GlycoNex. "AACR is one of the most influential oncology meetings in the world, and the opportunity to showcase the potential of GNX1021 to treat gastric cancer, an often-deadly cancer with few available therapies, highlights the importance of this program." Presentation Details: About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit . Contact s for GlycoNex, Inc. Investor Relations Tiberend Strategic Advisors, Inc. David Irish [email protected] Media Relations Eric Reiss [email protected] SOURCE GlycoNex, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Highlighting advancements in glycan-directed cancer immunotherapies and biosimilars NEW TAIPEI CITY, Taiwan, Jan. 8, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced today announced its participation in Biotech Showcase 2025. The event will take place from January 13-15, 2025, at the Hilton San Francisco Union Square, during J.P. Morgan Week. At Biotech Showcase, GlycoNex's leadership team, including Dr. Mei-Chun Yang, CEO, will meet with investors, potential partners, and other industry stakeholders to discuss the company's strategic initiatives, clinical progress, and innovations in glycan-targeted therapies and biosimilar development. Dr. Yang will highlight GlycoNex's progress with its development programs, including GNX1021, its antibody drug conjugate (ADC), and SPD8, a denosumab biosimilar currently in Phase 3 clinical trials. Details of the events are as follows: For more information or to request a meeting with GlycoNex during Biotech Showcase, please contact Seungwoo Yoo, Ph.D. ([email protected]) with Tiberend Strategic Advisors, Inc. About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells. GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit . Contact s for GlycoNex, Inc. Investor Relations Tiberend Strategic Advisors, Inc. David Irish [email protected] Media Relations Eric Reiss [email protected] SOURCE GlycoNex, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Exclusive rights granted for the development and commercialization of GlycoNex’s denosumab biosimilar, SPD8 NEW TAIPEI CITY, Taiwan I January 6, 2025 I GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced a licensing agreement for its denosumab biosimilar, SPD8. This marks GlycoNex’s strategic progress and a significant milestone in its global expansion strategy. Under the terms of the agreement, the licensee will obtain rights to develop, secure regulatory approval for, and commercialize SPD8 in the designated market. The licensing agreement includes milestone payments tied to the development and commercialization progress of SPD8, further supporting GlycoNex’s global business operations. SPD8 is a biosimilar to Prolia and Xgeva (denosumab), a widely used treatment to prevent osteoporosis and skeletal-related events in patients with bone metastases from solid tumors. Following the successful completion of Phase 1 clinical trials that confirmed its safety and pharmacokinetic equivalence to the reference drug, SPD8 has entered Phase 3 clinical trial in December 2024. “We are thrilled to collaborate with a renowned pharmaceutical partner,” said Dr. Mei-Chun Yang, CEO of GlycoNex. “This agreement reinforces our commitment to expanding global access to innovative therapies and establishes a strong foundation for our growth.” Denosumab, marketed as Prolia and Xgeva, is a leading therapy for managing osteoporosis and complications associated with bone metastases in cancer patients. In 2023, global sales of denosumab products reached USD 6.1 billion, underscoring the strong demand for treatments addressing skeletal-related events. As aging population and cancer prevalence continues to rise, the need for biosimilars like SPD8 is expected to grow, presenting a significant opportunity in the global market. In addition to advancing SPD8, GlycoNex is committed to strengthening its global strategy through innovative therapeutics. The company is actively pursuing partnerships to expand denosumab’s applications and recently announced a collaboration with Sterling Pharma Solutions to manufacture antibody-drug conjugates for clinical development. This multifaceted approach highlights GlycoNex’s dedication to addressing unmet medical needs through cutting-edge science and strategic alliances. About GlycoNex Inc. GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies that effectively inhibit tumor growth while minimizing side effects. GlycoNex possesses a robust pipeline led by GNX102, a humanized monoclonal antibody (mAb) designed to target abnormal sugar molecules in cancer cells.  GNX102 has successfully completed Phase 1 clinical trials with data demonstrating excellent safety and promising efficacy. GlycoNex is also advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue. GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit http://www.glyconex.com.tw . SOURCE: GlycoNex